Trade Breakfast Symposia and Workshops — ASN Events

Trade Breakfast Symposia and Workshops


  • Abbott - Trade Breakfast Symposium

Title: FreeStyle Libre T1DM Clinical Outcomes Trial Results (IMPACT)

Time: 7:00am - 8:00am
Location: Central C                                                                                                                                                             
Speaker: Dr Julia Mader
IMPACT is a randomised controlled study to evaluate the impact of Flash Glucose Monitoring on hypoglycaemia in well-controlled type 1 diabetes. Especially in patients with good glycaemic control there is a relevant risk of hypoglycaemia increasing the burden of disease. IMPACT is a 6-month, prospective, open, multicentre, randomised, controlled, two-arm study, which enrolled 241 adult patients with type 1 diabetes from 22 sites across Europe (Austria, Germany, Spain, Sweden and the Netherlands). The intervention group used sensor glucose data obtained by Flash Glucose Monitoring, whereas the control group used capillary fingerstick measurements for self-management of blood glucose. At 6 months, time in hypo-and hyperglycaemia was significantly reduced in the intervention group with similar A1c between groups. Patients in the intervention additionally reported an improvement in quality of life and treatment satisfaction. In this breakfast symposium, Dr. Julia Mader from the Medical University of Graz, Austria, will present the results of IMPACT, and also share global Flash Glucose Monitoring clinical use cases as part of the trial.

  • Lilly Diabetes - Trade Breakfast Symposium

Title: Insulin Pump Therapy
Time: 7:00am - 8:00am
Location: Room 7 
Speaker: Prof John Pickup

In this lecture Professor John Pickup will discuss the past, present and future of diabetes technology. To tell this story Professor Pickup will review how insulin pump therapy was invented and his integral role in its development. He will then look at modern diabetes technology and whether it is yet a quality treatment to help patients manage their diabetes. Finally he will look at potential future developments in diabetes technology and whether we can look forward to improved technology in the years to come.

  • Sanofi - Trade Breakfast Symposium

Title: Evolving Therapeutic Paradigm for Cardiometabolic Disease Management
Time: 7:00am - 8:00am
Location: Room 6
Speakers: A/Prof Michael d'Emden and A/Prof Jonathan Shaw

Diabetes has been recognized as in independent risk factor for cardiovascular disease (CVD) and is often accompanied by other CVD risk factors.  This clustering of risk factors for CVD and diagnosis of diabetes can present a complex management challenge. People living with diabetes are often diagnosed with CVD and its complications at a younger age.  Large vessel disease, such as coronary heart disease and stroke, represent the leading cause of mortality and morbidity in people living with diabetes.  Cardiometabolic disease risk factors such as uncontrolled blood glucose, hypertension and dyslipidaemia require heightened attention. Management of dyslipidaemia is a persistent challenge in the clinical setting, with those at highest risk for CVD not always achieving appropriate lipids levels with current treatment therapies. 
Can recent advances in treatments, such as PCSK9 inhibitors, change the way we manage people living with diabetes and cardiovascular disease?

  •  ADEA Workshop

Title: Research: Come with a great idea and leave with a great design 
Time: 3:30pm - 5:30pm
Location: Central C
Speakers: Prof Trisha Dunning and Prof Martha Funnell

A practical workshop for CDE's who have a research idea or question and want to design a study and enhance their research skills.  The workshop will focus on designing a research project and will include information on designing qualitative and quantitative research studies, quality improvement activities and evaluation studies.  The session will feature presentations by leading researchers Professor Trisha Dunning and Martha Funnell.  These presentations will be followed by small group activities where delegates can discuss their research ideas/questions with experienced researchers.


  • Lilly/Alliance - Trade Breakfast Symposium

Title: SGLT2 inhibitors – their expanding role in diabetes care
Time: breakfast served from 6.30am | session 7.00am to 8.00am
Location: Central B
(via Exhibition Hall)
Speakers: Per-Henrik Groop and Prof Juliana Chan 

This is a non-promotional Scientific Exchange Meeting, which all registered delegates are invited to attend. There is increased interest in SGLT2 inhibitors as glucose lowering agents as a result of recent clinical trials that have identified additional effects of this class of drugs including weight loss and blood pressure lowering. Interest has been further heightened by recent data that goes beyond these effects. This meeting will review not only the current role of SGLT2 inhibitors in the management of type 2 diabetes but also their place in the overall treatment plan as addressed in recently modified national and international guidelines. In addition, ongoing data on the longer term effects of these agents on other sites of diabetes related end organ injury including the kidney and their role as glucose lowering agents in combination with other drugs including insulin will be addressed. 

  • Novo Nordisk - Trade Breakfast Workshop

Title: Bridging the pharmacological treatment gap in obesity management
Time: 6:45am - 8:00am
Location: Cenbtral C
Speakers: Dr Arya M. Sharma, Dr Sarah Glastras, Dr Georgia Rigas and Dr Gary Kilov

Modest sustained weight loss of 5-10% is clinically meaningful and offers beneficial effects on cardiovascular and metabolic status, and improved quality of life. However, despite achieving modest weight loss by lifestyle interventions alone most patients are unable to sustain such weight loss. Typical long-term weight-loss seen with lifestyle interventions alone is in the 3-5% range. On the other end of the spectrum patients requiring sustainable weight loss of 15% or greater, may need to consider bariatric surgery. This leaves a wide ‘therapeutic gap’ for patients requiring sustainable weight-loss in the 5-15% range, which lies beyond what can be generally achieved with lifestyle intervention alone but well below the degree of weight loss that would suggest the need for surgery. Pharmacological options that may help bridge this gap remain sparse. While a number of weight loss medications have shown potential over the years, only two have been available for use in Australia. Liraglutide 3.0 mg is one such pharmacological option recently approved for chronic weight management in Australia that may help address this therapeutic gap. The first session will provide an overview of the benefits of 5-10% weight loss, the physiological barriers in maintaining weight loss, and introduce liraglutide 3.0 mg as a therapeutic option for sustainable weight loss1. In the second session, clinical application and experience with liralgutide 3.0 mg will be discussed via the presentation of three case studies.

  • AstraZeneca - Trade Breakfast Symposium

Title: BYDUREON Pen Launch – Practical Considerations for Patients with Type 2 Diabetes
Time: 7:00am - 8:00am
Location: Room 6 
Speakers: A/Prof Jonathan Shaw and A/Prof Jane Overland 

Advances in medicine over the last decade have allowed us to rethink the way we treat people with Type 2 Diabetes and provide individualised solutions to help them achieve goals. AstraZeneca is excited to share with you updates in its portfolio of medicines with the launch of the BYDUREON Pen (exenatide QW) in Australia.
This breakfast session will focus on BYDUREON Pen and the practical considerations when starting patients on the medicine. BYDUREON Pen is the first once weekly treatment available in Australia and represents a shift in the way we treat patients with type 2 diabetes. This meeting will cover the clinical trial programme for BYDUREON focusing on efficacy and safety compared with other glucose lowering medicines.

  • Roche - Trade Breakfast Symposium                                                                                                                                                

Title: Coffee with Roche: Living in the New Normal - Understanding the Changes in the Diabetes Landscape
Time: 7:00am - 8:00am
Location: Room 5 
Speakers: Kos Sclavos and Jayne Lehmann

Diabetes management is an ever-changing landscape, specifically in view of the proposed changes to test strip access for type 2 non-insulin users. With these changes to blood glucose strip access for some patients, the need for a focused team approach to diabetes management becomes even greater. This coffee table discussion will help shed light on how diabetes educators can navigate through this new environment.  

  • Joint ADS/NPS Interactive Workshop

Title: Type 2 diabetes: what’s next after metformin
Time: 9:00am - 10:30am?
Location: Central B (via Exhibition Hall)                                                                                                                               
Speakers: Natalie Raffoul, Anthony Russell, Gary Deed & Michelle Robins

This workshop will facilitate a case-based peer discussion focussing on glucose management of type 2 diabetes in the context of the updated Australian Diabetes Society (ADS) treatment algorithm. Discussion of the cases will explore factors influencing the choice of second and third-line blood glucose lowering medicines, the stepwise treatment of diabetes and determining when to escalate therapy as well as identifying the best approach to assess, manage and monitor risk of diabetes complications.

  • ADEA Writing for Publication Workshop

Time: 3:30pm - 4:30pm
Location: Central B (via Exhibition Hall)
Facilitators: Kate Marsh, Anne Marks, Nicole Duggan and Rachel Freeman

This year, the ADE Editorial Advisory Group will be facilitating an interactive and practical workshop ‘Writing for publication’ to assist novice authors to write for the ADE or other publications. Bring along an idea for an article and our facilitators will help you get started in your journey to get published.  Participants will work in small groups along with a facilitator, to brainstorm ideas and discuss the best format for writing up their work. Gain input from colleagues and a member of the ADE Editorial team and leave with a documented outline for your article and an understanding of the steps to getting published. In addition to feature articles covering a range of topics relevant to diabetes education or management, your articles could be based around an interesting or unusual case study, research you are doing in your workplace, teaching tips in the areas of your expertise, a review of the literature in a particular area of diabetes education or reflection on an aspect of your current practice. This is a not-to-be-missed session for those who are keen to get published but are not sure where to start.  Due to the interactive nature of the workshop, numbers will be limited so book your place now.

  • ADEA Business and Financial Workshop

Title: Price, costs and volume - a relationship to overcome break even
Time: 4:30pm - 5:30pm
Location: Central B (via Exhibition Hall)
Speaker: Robert Lockheart          

Understanding how your price, your costs and your time billed operate in your business is an important facet of a successful profitable business. In this 60 minute presentation Rob Lockhart Senior facilitator with Westpac’s Davidson Institute will take you through one of the simplest, most powerful tools in business, break even. You will understand; how to classify your costs and where to look for savings; the impact of price changes to your bottom line; and the impact of buying equipment on your business. Most importantly, Rob will take you through a step by step process to calculate your own break even.


  • Medtronic - Trade Breakfast Symposium

Title: Clinical Debate - Gold standard in Diabetes Management. Insulin Pump Therapy vs MDI
Time: 7:00am - 8:00am
Location: Room 8
Speakers: Dr Mark Forbes and Dr Michael d'Emden

A Healthcare Professional debate on the merits of Insulin Pump Therapy and Multiple Daily Injections, based on the examination of Australian patient case studies. Key points addressed will focus on patient outcomes, lifestyle implications, glucose monitoring options through review of CareLink patient data. 
Topics covered: 
1. Merits of Insulin Pump Therapy and Multiple Daily Injections
2. Patient outcomes, lifestyle implications, glucose monitoring, CareLink date review 

  • Ascenica - Trade Breakfast Symposium

Title: 'Accurate Blood Glucose Meters’ - Clinical and practical approach to new International Standards
Time: 7:30am - 8:30am
Location: Room 5
Speaker: A/Prof Kittie Wyne

This practical presentation aims to simplify the new accuracy standards (ISO 15197:2013) by outlining the real impact on patient’s management with case study scenarios and to compare the accuracy of the most commonly used blood glucose meters in Australia and around the world. It will also introduce the ‘Contour NEXT’ blood glucose meter from Ascensia Diabetes Car. For patients with diabetes, regular monitoring of blood glucose levels is an essential part of managing their diabetes therapy. Self-monitoring of BG (SMBG) is recommended especially for patients treated with multiple daily insulin injections or using an insulin pump. Devices for SMBG are thus daily companions for patients who have to rely on the values being precise and reliable enough to ensure an adequate glycemic control, especially when they calculate their insulin doses on the basis of current BG levels. If displayed BG values are, for example, higher than the true BG concentration, this might conceal hypoglycemia or lead to an inappropriately high insulin dose that might induce hypoglycemia.

  • MSD - Trade Breakfast Symposium

Title: Add-on therapy in Type 2 Diabetes: What is safe?
Time: 7:30am - 8:30am
Location: Central B
(via Exhibition Hall)
Speaker: Dr Konrad Kangru 

Primary care in Type 2 diabetes, especially without the additional support of an Endocrinologist or Diabetes clinic, can be a challenge for many isolated, regional and rural clinicians. Added to this are the issues of Cardiovascular safety for this group of patients, already at increased risk of adverse CV outcomes. For many GPs and Diabetes Educators without a large Diabetes patient population, the need to avoid harm to our patients may become a barrier to providing optimal care. In this session, Dr Konrad Kangru, a rural GP from Proserpine, Queensland, will explain the implications of recent Cardiovascular safety trials for the patients we deal with every day. They will help you to understand these studies, and share insights into how to interpret their findings to increase your confidence in managing patients with Diabetes as they progress beyond oral hypoglycaemic management alone

Topics Covered
Topic 1:  Management of Type 2 Diabetes patients in rural areas
Topic 2:  Interpreting cardiovascular safety trial results for the management of Type 2 Diabetes patients

  • Welch Allyn- Trade Breakfast Symposium

Title: Detecting vision-threatening diabetic retinopathy with the RETeval-DR electroretinography/pupillography system
Time: 7:30am - 8:30am
Location: Room 6
Speaker: Prof Quentin Davis

Diabetic retinopathy (DR) is a major cause of blindness worldwide, due in part to the challenge of detecting vision-threatening diabetic retinopathy (VTDR) in time for effective intervention. Contributing factors to low VTDR detection include patient characteristics (low compliance to the recommended annual dilated eye examination and patient aversion to eye dilation) and test method characteristics (significant failure rates and low sensitivity).  This presentation describes results from four clinical trials using the hand-held RETeval-DR device (Welch-Allyn, USA) for detecting VTDR. The RETeval-DR device measures an electroretinogram (ERG) and a pupillary response, both of which are well established to be affected by VTDR, and combines the information into a numerical value for VTDR detection. Four trials using five trial sites have tested 880 subjects (241 positive subjects) in the United States, United Kingdom, and Japan.  Weighting the reported sensitivity / specificity from each trial by the number of subjects, the sensitivity and specificity for the detection of VTDR is 88% and 69% respectively. Testing time, in any patient setting, is under 5 minutes and is non-mydriatic, non-invasive, providing immediate objective results, which may improve testing compliance. Concluding, the RETeval-DR device may reduce blindness from diabetic retinopathy by improving the detection of VTDR.

Topics Covered
Topic 1: Diabetic retinopathy
Topic 2: Clinical trial results for the detection of vision-threatening diabetic retinopathy